Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited has announced that its investigational radionuclide-drug conjugate, TLX591, for treating prostate cancer has received implied approval from China’s National Medical Products Administration to join an international Phase III clinical trial. This trial, involving over 500 patients across multiple countries, aims to evaluate the efficacy and safety of TLX591 in combination with standard care. The product, developed in collaboration with Telix Pharmaceuticals, offers a shorter treatment cycle and improved safety profile compared to existing therapies, potentially redefining the treatment standard for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company involved in the pharmaceutical industry, focusing on innovative nuclear medicine products. The company is dedicated to the global development and registration of these products, with a particular emphasis on anti-tumor diagnosis and treatment.
Average Trading Volume: 32,936,411
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.61B
For an in-depth examination of 0512 stock, go to TipRanks’ Overview page.